Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q3 2024 Earnings Presentation
12 slides from Bionano Genomics's earnings presentation, Nov 13, 2024
Slide 1: Q3 2024 Financial Results Webcast & Call
bionano Q3 2024 Financial Results Webcast & Call November 13! 2024
Slide 2: ren aa earl Ic
ren aa earl Ic eta cess alee Seer tt tn nen HA ig pe aaa fap a eeinlrpe rot
Slide 3: Strategic pillars underpinning the transformed Bionano
Strategic pillars underpinning the transformed Bionano Enable adoption of VIA™ Leverage existing customer software for more OGM base to increase utilization utilization at routine use sites and drive menu expansion 4 ; Improve efficiencies across the organization by leveraging existing customer base
Slide 4: Corporate Update
Slide 5: Q3 2024 Financial Highlights
Revenue Q3 2024 Financial Highlights * Q3 revenues: $6.1M 380 (-35% vs Q3’23) = $6.6M core product & software sales offset by a $0.5M write-down of aged receivables * GAAP gross margin of (139)%; non-GAAP gross margin 26% » GAAP OpEx $35.5M; non-GAAP OpEx $16.1M 3.0 70 5.0 30 - Q3 OGM installed base
Slide 6: Bionano Publications
Bionano Publications - 83 Publications in 3Q’24, +12% yly * Total number of clinical research subjects covered in publications: YTD (1Q—3Q) +82% yly * 849 cases 1Q23 - 3Q23 * 1,547 cases 1Q24 - 3Q24 * Over ~6,800 published human clinical research samples » Only ~500 samples before 2021 * +~1,100 in
Slide 7: Significant milestone for OGM with establishment of Category I CPT code
Significant milestone for OGM with establishment of Category | CPT code for OGM in hematological malignancy analysis American Medical Association (AMA) CPT Code for OGM * New Category | Current Procedural Terminology (CPT) code for the use of Code # 81195 OGM in cytogenomic genome-wide analysis to .
Slide 8: Financial Overview
Financial Overview bionano
Slide 9: Important steps to help us deliver against our vision
Important steps to help us deliver against our vision = Equity Financings Y Registered direct offering in April 2024, with gross proceeds of ~$10M Y Registered direct offering in July 2024, with gross proceeds of ~$10M ¥ Registered direct offering in October 2024, with gross proceeds of ~$3M ¥ Since
Slide 10: Focused on accelerating revenue growth, operating efficiently, and raising capital
Bionano is focused on accelerating revenue growth, operating efficiently, and raising capital that will allow us to extend our cash runway 2024 Guidance Streamlined Business Focus + Adoption of VIA™ software driving OGM utilization across clinical sites « Leverage existing customer / install base to
Slide 11: Questions & Answers
Questions & Answers bionano
Slide 12: Thank you.
= Thank you. a